Efficacy of photodynamic therapy with intraperitoneal introduction photosensitizer Amidoaminchlorine on rat sarcoma M1 model was studied. The aim of this study was to determine minimum effective dose of photosensitizer and parameters of laser radiation for achievement of tumor full regress. Dynamics of photosensitizer accumulation in tumor and healthy tissues was studied to definite the time of photodynamic therapy. Antitumor efficacy different doses of photosensitizer and various parameters of laser radiation were investigated. As a result, optimal term of photodynamic therapy, photosensitizer minimum effective dose and parameters of laser irradiation were established.
(155,0 ± 44,0 нг/л проти 35,9 ± 20,8 нг/л), вищий індекс маси міокарда лівого шлуночка (147,50 ± 3,46 г/м 2 проти 135,30 ± 1,74 г/м 2 ), частіше спостерігались ожиріння (42,9 проти 37,5 %), аномалії розвитку нирок (2,7 проти 0,8 %), облітеруючий атеросклероз нижніх кінцівок (2,0 проти 0,2 %), структурні зміни наднирників (3,0 проти 1,2 %), нефропатія (1,3 проти 0,2 %), вищий ступінь серцевої недостатності (СН 2А стадії; 16,9 проти 8,5 %). Ступінь зниження офісного АТ серед пацієнтів, які приймали 3 антигіпертензивні препарати та більше, загалом становив для САТ 43,47 ± ± 0,65 мм рт.ст., для ДАТ -20,33 ± 0,74 мм рт.ст., р < 0,001
Objective: Aim. Evaluate the therapeutic efficacy of fixed triple combination of valsartan / amlodipine / hydrochlorothiazide compared a double fixed combination of valsartan / amlodipine in patients with arterial hypertension. Design and method: The study included 50 patients with moderate and severe arterial hypertension. Patients were divided into 2 groups. The first group (n = 25) received fixed triple combination of 160 mg valsartan / 5 mg amlodipine / 12.5 mg hydrochlorothiazide once daily, in the morning for 1 month. Patients in the second group (n = 25) received a double fixed combination of 160 mg valsartan / 5 mg amlodipine once a day, in the morning for 1 month. If necessary, dose was titrated to 320/10 / 12.5 mg (valsartan / amlodipine / hydrochlorothiazide) or 320/10 mg (valsartan / amlodipine). After 3 months of treatment was control of therapy. Results: The average age of patients 54.9 ± 1.8 (25–75) years, BMI 31.2 ± 0.7 kg / m2. Office SBP/DBP at the beginning 161.7 ± 1.8/98.5 ± 1.4 mmHg, HR 70.7 ± 1.4 beats / min. 24 SBP/DBP 143.8 ± 1.1/92.4 ± 1.2 mm Hg. 24HR 71.5 ± 1.5 beats / min. The decrease 24SBP/DBP was 18.0 / 16.1 mm Hg (p < 0,05) on (val/aml) and 23,8 / 20,7 mm Hg (p < 0,05) on (val/aml/HTZ). The decrease day time SBP/DBP - 19.4 / 17.8 mm Hg (p < 0,05) on (val/aml) and 17,8 / 22,6 mm Hg (p < 0,05) on (val/aml/HTZ). Decrease mean nocturnal SBP/DBP 17.0 / 12.1 mm Hg (p < 0,05) on (val/aml) and 20,5 / 18,2 mm Hg (p < 0,05) on (val/aml/HTZ) combination. Achievement of target BP at ABPM was 77.3% - in the double (val/aml) combination and 95.2% in the triple (val/aml/HTZ) combination. Conclusions: The triple fixed combination (val/aml/HTZ) was more effective in reducing blood pressure with daily monitoring compared to a double fixed (val/aml) combination which was not increase in side effects.
Background. Obstructive sleep apnea (OSA), especially severe, is related to fatal and non-fatal cardiovascular events. OSA and arterial hypertension (AH) have significant correlations, and this comorbidity is very common and is associated with an increased risk of cardiovascular diseases. One of the causes is an increased arterial stiffness. Aortic pulse wave velocity is a highly reproducible noninvasive indicator of arterial stiffness recommended in current guidelines for evaluation of cardiovascular risk. The purpose of the study was to assess the arterial stiffness changes in patients with AH and OSA and possibilities of its correction by continuous positive airway pressure (CPAP) therapy. Materials and methods. One hundred and eighty-five patients with mild and moderate AH (49.80 ± ± 0.80 years old) were enrolled in the study and divided into groups: group 1 — those who had OSA (n = 148), group 2 — individuals without OSA (controls, n = 37). They underwent clinical and special examination: unattended somnography by dual-channel portable monitor device, evaluation of daytime sleepiness by Epworth Sleepiness Scale, office and ambulatory blood pressure monitoring, echocardiography and assessment of pulse wave velocity. The 10-month follow-up study included 105 patients, who were divided into 4 subgroups: A — those with moderate to severe OSA on CPAP (n = 23); B — individuals with moderate to severe OSA without CPAP (n = 29); C — patients with mild OSA (n = 29); D — people without OSA (controls, n = 24). All examinees received similar antihypertensive therapy according to 2013 European Society of Hypertension/European Society of Cardiology Guidelines. Results. Patients with AH and OSA (mean apnea-hypopnea index of 38.10 ± 2.51 events/h) compared to those without OSA (mean apnea-hypopnea index of 3.02 ± 0.25 events/h) had significantly higher body mass index (35.20 ± 0.57 kg/m2 vs 30.60 ± 0.79 kg/m2, P < 0.001), as well as blood glucose level (107.2 ± 2.2 mg/dl vs 98.0 ± 2.5 mg/dl, P = 0.045), uric acid level (6.17 ± 0.10 mg/dl vs 5.5 ± 0.3 mg/dl, P = 0.048) and left ventricular mass index (115.80 ± 2.39 g/m2 vs 104.60 ±± 4.56 g/m2, P = 0.035). During 10 months of follow-up, patients with AH and OSA on CPAP therapy reported a significant decrease in pulse wave velocity in elastic arteries (from 12.20 ± 0.63 m/s to 10.05 ± 0.43 m/s, P = 0.009), office systolic blood pressure (from 143.8 ± 132.7 mm Hg to 132.70 ± ± 2.33 mm Hg; P = 0.021) and diastolic blood pressure (from 93.80 ± 3.31 mm Hg to 86.00 ± 3.19 mm Hg; P = 0.012). Central systolic blood pressure also decreased (from 130.30 ± ± 3.97 mm Hg to 119.70 ± 2.97 mm Hg; P = 0.012). Conclusions. Combination of continuous positive airway pressure therapy and antihypertensive treatment improves arterial elasticity and helps achieve target blood pressure in hypertensive patients with moderate to severe obstructive sleep apnea.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.